MTOR and type 2 diabetes mellitus: Metformin, which has been a first-line therapy for T2DM for half a century, is suspected to have anticancer effect [68,69], and the biologically plausible mechanisms could be activation of AMP-activated protein kinase, and then inhibition of mammalian target of rapamycin, a downstream effector of growth factor signaling [70].